Published in Diabetes Care on January 03, 2013
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int (2015) 0.86
Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis. Nutrients (2015) 0.85
Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab (2013) 0.82
Serum sclerostin in hepatitis C virus infected patients. J Bone Metab (2014) 0.79
Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res (2016) 0.79
Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J (2015) 0.77
Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men? Osteoporos Int (2016) 0.76
Sclerostin serum levels in patients with systemic autoimmune diseases. Bonekey Rep (2016) 0.76
Association of circulating sclerostin with vascular calcification in Afro-Caribbean men. Atherosclerosis (2015) 0.75
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.75
DKK1 rescues osteogenic differentiation of mesenchymal stem cells isolated from periodontal ligaments of patients with diabetes mellitus induced periodontitis. Sci Rep (2015) 0.75
Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. Osteoporos Int (2016) 0.75
Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy. Bone (2017) 0.75
The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther (2017) 0.75
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med (1997) 5.25
LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science (2007) 4.27
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest (2005) 3.00
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis (1997) 2.45
An updated overview on Wnt signaling pathways: a prelude for more. Circ Res (2010) 2.40
Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol (2007) 2.17
The WNT signalling pathway and diabetes mellitus. Diabetologia (2008) 2.00
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev (2005) 1.88
Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension (2010) 1.84
A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res (2002) 1.72
Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation (2003) 1.64
[Carotid ultrasound in the assessment of preclinical atherosclerosis. Distribution of intima-media thickness values and plaque frequency in a Spanish community cohort]. Med Clin (Barc) (2005) 1.59
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics (2010) 1.53
Glycemic control and cardiovascular disease--should we reassess clinical goals? N Engl J Med (2005) 1.49
The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One (2011) 1.40
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant (2011) 1.27
Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2011) 1.26
Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.25
Wnt4/β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res (2010) 1.24
Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics (2009) 1.14
Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes. Vascul Pharmacol (2011) 1.14
Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int (2012) 1.13
Induction of the Wnt antagonist, Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia. J Cereb Blood Flow Metab (2008) 1.13
High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone (2009) 1.04
Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women. J Clin Endocrinol Metab (2012) 0.98
Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? Circ Res (2006) 0.94
Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis (2012) 0.93
Hyperhomocysteinemia: a biochemical link between bone and cardiovascular system diseases? J Endocrinol Invest (2009) 0.84
Advanced oxidation protein products induce vascular calcification by promoting osteoblastic trans-differentiation of smooth muscle cells via oxidative stress and ERK pathway. Ren Fail (2009) 0.79
Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res (2012) 1.61
[Effect of milk product with soy isoflavones on quality of life and bone metabolism in postmenopausal Spanish women: randomized trial]. Med Clin (Barc) (2011) 1.40
Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2011) 1.26
Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol (2012) 1.26
The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int (2005) 1.05
Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy. Thyroid (2008) 0.95
[Thyrotoxic periodic paralysis: an increasingly common complication of hyperthyroidism]. Endocrinol Nutr (2012) 0.91
Improvement of bone formation biomarkers after 1-year consumption with milk fortified with eicosapentaenoic acid, docosahexaenoic acid, oleic acid, and selected vitamins. Nutr Res (2010) 0.88
Consensus document for the detection and management of chronic kidney disease. Nefrologia (2014) 0.88
Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin Exp Res (2010) 0.88
Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine (2012) 0.87
Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas (2009) 0.86
Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine (2011) 0.86
Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study. Aging Clin Exp Res (2009) 0.85
Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol (2011) 0.85
Position statement: hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol Nutr (2013) 0.83
FGF23 in type 2 diabetic patients: relationship with bone metabolism and vascular disease. Diabetes Care (2014) 0.82
Susceptibility for postmenopausal osteoporosis: interaction between genetic, hormonal and lifestyle factors. Calcif Tissue Int (2004) 0.82
Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. Menopause (2011) 0.82
Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. Menopause (2012) 0.80
[Cathepsin K: biological aspects and therapeutic possibilities]. Med Clin (Barc) (2008) 0.79
Osteocalcin and atherosclerosis: a complex relationship. Diabetes Res Clin Pract (2010) 0.79
Serum osteoprotegerin and sex steroid levels in patients with prostate cancer. J Androl (2011) 0.79
[Vitamin D hormone system and diabetes mellitus: lessons from selective activators of vitamin D receptor and diabetes mellitus]. Endocrinol Nutr (2012) 0.78
[Pentosidine: a new biomarker in diabetes mellitus complications]. Med Clin (Barc) (2010) 0.78
Development of a new tool for assessing health-related quality of life in patients with primary hyperparathyroidism. Health Qual Life Outcomes (2013) 0.78
Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment. Ther Adv Endocrinol Metab (2013) 0.78
Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpress® (OSTEOXPRESS Study). Aging Clin Exp Res (2010) 0.77
Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer. Endocrinol Nutr (2011) 0.77
Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. Menopause (2010) 0.77
[Cardiovascular disease and bone metabolism]. Endocrinol Nutr (2011) 0.77
Osteocalcin: a link between bone homeostasis and energy metabolism. Endocrinol Nutr (2012) 0.76
Etidronate and glucocorticoid induced osteoporosis. J Rheumatol (2005) 0.75
[Anabolic therapy of osteoporosis]. Med Clin (Barc) (2005) 0.75
A nutritional intervention study with hydrolyzed collagen in pre-pubertal spanish children: influence on bone modeling biomarkers. J Pediatr Endocrinol Metab (2011) 0.75
Treatment holidays in patients with postmenopausal osteoporosis: whom and when? Endocrinol Nutr (2012) 0.75
[Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up]. Endocrinol Nutr (2013) 0.75
[Hypophosphatasia: new therapeutic approaches]. Med Clin (Barc) (2009) 0.75
[Fibrous dysplasia of bone in a young male]. Endocrinol Nutr (2009) 0.75
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors. Endocrinol Nutr (2012) 0.75
[Stroke in a patient with marked thinness, diabetes mellitus and basal ganglia calcifications]. Endocrinol Nutr (2013) 0.75
Bone turnover markers in patients with prostate carcinoma: influence of sex steroids levels. J Bone Miner Metab (2013) 0.75
[ACTH-independent macronodular adrenal hyperplasia and subclinical Cushing's syndrome]. Med Clin (Barc) (2011) 0.75
[Wnt pathway and sclerostin as new targets for assessment and treatment of osteoporosis]. Med Clin (Barc) (2012) 0.75
Neonatal diabetes: genetic implications in treatment. Endocrinol Nutr (2008) 0.75
An unusual association of neuroendocrine tumors in MEN 1A. Pituitary (2012) 0.75
Diagnosis and management of bilateral diaphyseal femoral fracture. Endocrine (2012) 0.75